Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H2 2018, provides an overview of the Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) pipeline landscape.
Uterine fibroids are benign tumors that originate in the uterus (womb). Although they are composed of the same smooth muscle fibers as the uterine wall (myometrium), they are much denser than normal myometrium. Uterine fibroids are usually round. The most common symptoms of uterine fibroids include heavy menstrual bleeding, prolonged menstrual periods seven days or more of menstrual bleeding, pelvic pressure or pain, frequent urination, difficulty emptying bladder, constipation and backache or leg pains.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) pipeline guide also reviews of key players involved in therapeutic development for Uterine Leiomyoma (Uterine Fibroids) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 3, 2, 4 and 2 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.
Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders).
- The pipeline guide reviews pipeline therapeutics for Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Uterine Leiomyoma (Uterine Fibroids) - Overview
Uterine Leiomyoma (Uterine Fibroids) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Uterine Leiomyoma (Uterine Fibroids) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Uterine Leiomyoma (Uterine Fibroids) - Companies Involved in Therapeutics Development
AbbVie Inc
Addex Therapeutics Ltd
Auritec Pharmaceuticals Inc
Bayer AG
BioSpecifics Technologies Corp
GeneScience Pharmaceuticals Co Ltd
Immunitor Inc
Kissei Pharmaceutical Co Ltd
Luye Pharma Group Ltd
Ogeda SA
Repros Therapeutics Inc
Richter Gedeon Nyrt
Takeda Pharmaceutical Co Ltd
Uterine Leiomyoma (Uterine Fibroids) - Drug Profiles
cetrorelix - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
collagenase clostridium histolyticum - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CTX-30916 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Activate Progesterone Receptor for Uterine Fibroids - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EC-313 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
elagolix sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fezolinetant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KLH-2109 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
leuprolide acetate SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
relugolix - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize FSH Receptor and LH Receptor for Women's Health - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
telapristone acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
triptorelin acetate ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ulipristal acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
V-Myoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vilaprisan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VPE-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Uterine Leiomyoma (Uterine Fibroids) - Dormant Projects
Uterine Leiomyoma (Uterine Fibroids) - Discontinued Products
Uterine Leiomyoma (Uterine Fibroids) - Product Development Milestones
Featured News & Press Releases
Jul 10, 2018: Myovant Sciences Announces Completion of Screening for Phase 3 LIBERTY 1 Study Evaluating Relugolix in Women with Uterine Fibroids
Jun 29, 2018: CHMP granted a positive opinion for Ulipristal Acetate Gedeon Richter
May 18, 2018: PRAC recommends new measures to minimise risk of rare but serious liver injury with Esmya for fibroids
Apr 27, 2018: AbbVie Presents New Investigational Data for Elagolix at the 2018 American College of Obstetricians and Gynecologists (ACOG) Annual Meeting
Apr 26, 2018: Allergan to Present New Data at the American College of Obstetrics and Gynecology 67th Annual Clinical and Scientific Meeting 2018
Apr 23, 2018: ObsEva Announces Upcoming Presentations Related to its Endometriosis and Uterine Fibroid Development Programs with its Novel Oral GnRH Receptor Antagonist OBE2109 (KLH-2109)
Mar 15, 2018: Health Canada to conduct review of a new potential safety risk of Fibristal (ulipristal acetate), a medication used to treat fibroids
Mar 13, 2018: AbbVie Announces Positive Topline Results from Second Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids
Mar 12, 2018: BioSpecifics Technologies Announces Presentation of Interim Data from Phase 1 Study of CCH for the Treatment of Uterine Fibroids at 65th Annual Scientific Meeting of the Society for Reproductive Investigation
Feb 28, 2018: Allergan Announces FDA Has Extended The Ulipristal Acetate NDA Review Period To August 2018
Feb 21, 2018: AbbVie Announces Positive Topline Results from Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids
Feb 16, 2018: Esmya: no new treatment courses prescribed until further notice
Feb 09, 2018: Women taking Esmya for uterine fibroids to have regular liver tests while EMA review is ongoing
Dec 01, 2017: EMA starts review of Esmya for uterine fibroids
Nov 09, 2017: Myovant Sciences Announces Positive Top-line Results from Takeda's Phase 3 Study Evaluating the Efficacy and Safety of Relugolix for the Treatment of Pain Associated with Uterine Fibroids
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids), H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by AbbVie Inc, H2 2018
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Addex Therapeutics Ltd, H2 2018
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Auritec Pharmaceuticals Inc, H2 2018
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Bayer AG, H2 2018
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by BioSpecifics Technologies Corp, H2 2018
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by GeneScience Pharmaceuticals Co Ltd, H2 2018
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Immunitor Inc, H2 2018
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Kissei Pharmaceutical Co Ltd, H2 2018
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Luye Pharma Group Ltd, H2 2018
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Ogeda SA, H2 2018
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Repros Therapeutics Inc, H2 2018
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Richter Gedeon Nyrt, H2 2018
Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018
Uterine Leiomyoma (Uterine Fibroids) - Dormant Projects, H2 2018
Uterine Leiomyoma (Uterine Fibroids) - Discontinued Products, H2 2018
List of Figures
Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids), H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products by Targets, H2 2018
Number of Products by Stage and Targets, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
